Primary antiphospholipid syndrome: A low-grade auto-inflammatory disease?

Rheumatology

Volumn 47, Issue 12, 2008, Pages 1832-1837

  Ames, P R J ^a,b,h   Antinolfi, I ^c   Ciampa, A ^d   Batuca, J ^e   Scenna, G ^c   Lopez, L R ^f   Delgado Alves, J ^e   Iannaccone, L ^e   Matsuura, E ^g  

^a Immunoclot Ltd   (United Kingdom)

^b ROYAL PRESTON HOSPITAL   (United Kingdom)

^c CARDARELLI HOSPITAL   (Italy)

^d S G MOSCATI HOSPITAL   (Italy)

^e UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^f Division of Medicine   (United States)

^g OKAYAMA UNIVERSITY   (Japan)

^h NONE   (United Kingdom)

Author keywords

Anti phospholipid syndrome; C reactive protein; Neopterin; Serum amyloid A; Soluble CD14

Indexed keywords

AMYLOID A PROTEIN; BETA2 GLYCOPROTEIN 1 ANTIBODY; C REACTIVE PROTEIN; CD14 ANTIGEN; IMMUNOGLOBULIN G; LOW DENSITY LIPOPROTEIN; NEOPTERIN; SOLUBLE CD4 ANTIGEN;

ADULT; AGE; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; ARTICLE; AUTOINFLAMMATORY DISEASE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNE RESPONSE; INFLAMMATION; LABORATORY TEST; MALE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THROMBOPHILIA;

ADULT; AGED; ANTIGENS, CD14; ANTIPHOSPHOLIPID SYNDROME; AUTOANTIBODIES; BETA 2-GLYCOPROTEIN I; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFLAMMATION; MALE; MIDDLE AGED; NEOPTERIN; SERUM AMYLOID A PROTEIN; THROMBOPHILIA;

EID: 56649123530     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken382     Document Type: Article

References (44)

1. Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
2. Hattori N, Kuwana M, Kaburaki J, Mimori T, Ikeda Y, Kawakami Y. T cells that are autoreactive to beta2-glycoprotein I in patients with antiphospholipid syndrome and healthy individuals. Arthritis Rheum 2000;43:65-75.
3. Arai T, Yoshida K, Kaburaki J et al. Autoreactive CD4(+) T-cell clones to beta2-glycoprotein I in patients with antiphospholipid syndrome: Preferential recognition of the major phospholipid-binding site. Blood 2001;98:1889-96.
4. Meroni PL, Raschi E, Testoni C et al. Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: Effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum 2001;44:2870-78.
5. Sorice M, Longo A, Capozzi A et al. Anti-beta2-glycoprotein I antibodies induce monocyte release of tumour necrosis factor alpha and tissue factor by signal transduction pathways involving lipid rafts. Arthritis Rheum 2007;56:2687-97.
6. Ahmed K, Vianna JL, Khamashta MA, Hughes GRV. IL-2, IL-6 and TNF levels in primary antiphospholipid syndrome. Clin Exp Rheumatol 1992;10:503.
7. Bertolaccini ML, Atsumi T, Lanchbury JS et al. Plasma tumor necrosis factor alpha levels and the -238*A promoter polymorphism in patients with antiphospholipid syndrome. Thromb Haemost 2001;85:198-203.
8. Forastiero RR, Martinuzzo ME, de Larrañaga GF. Circulating levels of tissue factor and proinflammatory cytokines in patients with primary antiphospholipid syndrome or leprosy related antiphospholipid antibodies. Lupus 2005;14 129-36.
9. Hamid C, Norgate K, D'Cruz DP et al. Anti-beta2-GPI-antibody-induced endothelial cell gene expression profiling reveals induction of novel pro-inflammatory genes potentially involved in primary antiphospholipid syndrome. Ann Rheum Dis 2007;66:1000-7.
10. Ames PRJ, Tommasino C, Brancaccio V, Ciampa A. C-reactive protein in primary antiphospholipid syndrome. J Rheumatol 2007;34:650.
11. Sailer T, Vormittag R, Pabinger I et al. Inflammation in patients with lupus anticoagulant and implications for thrombosis. J Rheumatol 2005;32:462-8.
12. Sidelmann JJ, Sjoland JA, Gram J et al. Lupus anticoagulant is significantly associated with inflammatory reactions in patients with suspected deep vein thrombosis. Scand J Clin Lab Invest 2007;67:270-9.
13. Miesbach W, Gokpinar B, Gilzinger A, Claus D, Scharrer I. Predictive role of hs-C-reactive protein in patients with antiphospholipid syndrome. Immunobiology 2005;210:755-60.
14. Hoffmann G, Wirleitner B, Fuchs D. Potential role of immune system activation-associated production of neopterin derivatives in humans. Inflamm Res 2003;52:313-21.
15. Bazil V, Strominger JL. Shedding as a mechanism of down-modulation of CD14 on stimulated human monocytes. J Immunol 1991;147:1567-74.
16. Bas S, Gauthier BR, Spenato U, Stingelin S, Gabay C, CD14 is an acute-phase protein. J Immunol 2004;172:4470-9.
17. Chang M, Binder CJ, Torzewski M, Witztum JL. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci USA 2002; 99:13043-8.
18. Tabuchi M, Inoue K, Usui-Kataoka H et al. The association of C-reactive protein with an oxidative metabolite of LDL and its implication in atherosclerosis. J Lipid Res 2007;48:768-81.
19. Brancaccio V, Ames PRJ, Glynn J, Iannaccone L, Mackie IJ. A rapid screen for lupus anticoagulant (LA) by comparing a sensitive and insensitive aPTT reagent provides also good discrimination from oral anticoagulants, congenital factor deficiency and heparin. Blood Coagul Fibrin 1997;8:155-60.
20. Zhang N, Ahsan MH, Purchio AF, West DB. Serum amyloid A-luciferase transgenic mice: Response to sepsis, acute arthritis, and contact hypersensitivity and the effects of proteasome inhibition. J Immunol 2005;174:8125-34.
21. Sodin-Šemrl S, Žigon P, Čučnik S et al. Serum amyloid A in autoimmune thrombosis. Autoimmun Rev 2006;1:21-7.
22. Cai H, Song C, Endoh I et al. Serum amyloid A induces monocyte tissue factor. J Immunol 2007;178:1852-60.
23. Cai H, Song C, Lim IG, Krilis SA, Geczy CL, McNeil HP. Importance of C-reactive protein in regulating monocyte tissue factor expression in patients with inflammatory rheumatic diseases. J Rheumatol 2005;32:1224-31.
24. Burnand KG, Gaffney PJ, McGuinness CL, Humphries J, Quarmby JW, Smith A. The role of the monocyte in the generation and dissolution of arterial and venous thrombi. Cardiovasc Surg 1998;6:119-25.
25. López-Pedrera C, Buendia P, Cuadrado MJ et al. Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kappaB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK pathway. Arthritis Rheum 2006;54:301-11.
26. Hasunuma Y, Matsuura E, Makita Z, Katahira T, Nishi S, Koike T. Involvement of β2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 1997;7:569-73.
27. Kobayashi K, Kishi M, Atsumi T et al. Circulating oxidized LDL forms complexes with beta2-glycoprotein I: Implication as an atherogenic autoantigen. J Lipid Res 2003;44:716-26.
28. Kasahara J, Kobayashi K, Maeshima Y et al. Clinical significance of serum oxidized low-density lipoprotein/beta2-glycoprotein I complexes in patients with chronic renal diseases. Nephron Clin Pract 2004;98:15-24.
29. Ames PRJ, Alves J, Inanc M, Isenberg DA, Nourooz-Zadeh J. Oxidative stress in systemic lupus erythematosus and allied disorders with vascular involvement. Rheumatology 1999;38:529-34.
30. Cottone S, Lorito MC, Riccobene R et al. Oxidative stress, inflammation and cardiovascular disease in chronic renal failure. J Nephrol 2008;21:175-9.
31. Ames PRJ, Nourooz-Zadeh J, Tommasino C, Alves J, Brancaccio V, Anggard EE. 'Oxidative stress' in primary antiphospholipid syndrome Thromb Haemost 1998;79:447-9.
32. Iuliano L, Praticò D, Ferro D et al. Enhanced lipid peroxidation in patients positive for antiphospholipid antibodies. Blood 1997;90:3931-5.
33. Delgado Alves J, Ames PRJ, Donohue S, Norouz-Zadeh J, Isenberg DA. Antibodies towards high-density lipoprotein, Apo-A-I and cardiolipin inversely correlate to paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. Possible atherogenic mechanisms. Arthritis Rheum 2002;46:2686-94.
34. Yamaguchi Y, Seta N, Kaburaki J, Kobayashi K, Matsuura E, Kuwana M. Excessive exposure to anionic surfaces maintains autoantibody response to beta-2-glycoprotein I in patients with antiphospholipid syndrome. Blood 2007;110:4312-8.
35. Venugopal SK, Devaraj S, Jialal I. Macrophage conditioned medium induces the expression of C-reactive protein in human aortic endothelial cells: potential for paracrine/autocrine effects. Am J Pathol 2005;166:1265-71.
36. Sun H, Koike T, Ichikawa T et al. C-reactive protein in atherosclerotic lesions. Its origin and pathophysiological significance. Am J Pathol 2005;167:1139-48.
37. Meek RL, Urieli-Shoval S, Benditt EP. Expression of apolipoprotein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells: Implications for serum amyloid A function. Proc Natl Acad Sci USA 1994;91:3186-90.
38. Aboyans V, Criqui MH, Denenberg JO, Knoke JD, Ridker PM, Fronek A. Risk factors for progression of peripheral arterial disease in large and small vessels. Circulation 2006;113:2623-9.
39. Johnson BD, Kip KE, Marroquin OC et al. Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: The national heart, lung, and blood institute-sponsored women's ischemia syndrome evaluation (WISE). Circulation 2004;109:726-32.
40. Erren M, Reinecke H, Junker R et al. Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries. Arterioscler Thromb Vasc Biol 1999;19:2355-63.
41. Ames PRJ, Margarita A, Delgado Alves J, Tommasino C, Iannaccone L, Brancaccio V. Anticardiolipin antibody titre and plasma homocysteine independently predict intima-media thickness of carotid arteries in subjects with idiopathic antiphospholipid antibodies. Lupus 2002;11:208-14.
42. Margarita A, Batuca J, Scenna G et al. Subclinical atherosclerosis in primary antiphospholipid syndrome. Ann NY Acad Sci 2007;1108:475-80.
43. Ames PRJ, Tommasino C, Alves J et al. Antioxidant susceptibility of pathogenic pathways in subjects with antiphospholipid antibodies. A pilot study. Lupus 2000;9:1-8.
44. Zhou H, Wolberg AS, Roubey RA. Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep. Blood 2004;104:2353-8.